Anaphylaxis following H1N1 pandemic vaccines: Safety data in perspective

Vaccine

Volumn 29, Issue 37, 2011, Pages 6402-6407

  Tavares, Fernanda ^a   Delaigle, Aurelie ^a   Slavin, Dorothy ^b   Bauchau, Vincent ^a   Fries, Louis ^b   Seifert, Harry ^b  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Anaphylaxis; Brighton Collaboration Case Definition; H1N1 pandemic vaccine; Postmarketing; Safety

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ARTICLE; CHILD; CLINICAL ASSESSMENT; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FEMALE; FIRST USE SYNDROME; HUMAN; INFANT; INFLUENZA A (H1N1); INFLUENZA VACCINATION; KOUNIS SYNDROME; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SHOCK;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANAPHYLAXIS; HUMANS; IMMUNOGLOBULIN E; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MASS VACCINATION; VACCINATION;

EID: 80051569958     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.026     Document Type: Article

References (35)

1. Rüggeberg J.U., Gold M.S., Bayas J.M., Blum M.D., Bonhoeffer J., Friedlander S., et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25:5675-5684.
2. Erlewyn-Lajeunesse M., Bonhoeffer J., Ruggeberg J.U., Heath P.T. Anaphylaxis as an adverse event following immunisation. J Clin Pathol 2007, 60:737-739.
3. Global Advisory Committee on Vaccine Safety (GACVS), WHO secretariat Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS. Expert Rev Vaccines 2009, 8:705-716.
4. Bohlke K., Davis R.L., Marcy S.M., Braun M.M., DeStefano F., Black S.B., et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003, 112:815-820.
5. Nokleby H. Vaccination and anaphylaxis. Curr Allergy Asthma Rep 2006, 6:9-13.
6. Peng M.M., Jick H. A population-based study of the incidence, cause, and severity of anaphylaxis in the United Kingdom. Arch Intern Med 2004, 164:317-319.
7. Brotherton J.M.L., Gold M.S., Kemp A.S., McIntyre P.B., Burgess M.A., Campbell-Lloyd S. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 2008, 179:525-533.
8. Babl F.E., Lewena S., Brown L. Vaccination-related adverse events. Pediatr Emerg Care 2006, 22:514-519.
9. World Health Organization (WHO) 2009. Annex B: recognition and treatment of anaphylaxis. [Accessed 21 March 2011]. http://www.wpro.who.int/internet/files/pub/116/44.pdf.
10. Li J.T., Rank M.A., Squillace D.L., Kita H. Ovalbumin content of influenza vaccines. J Allergy Clin Immunol 2010, 125:1412-1413.
11. Waibel K.H., Gomez R. Reply to Li et al., 2010: ovalbumin content of influenza vaccines. J Allergy Clin Immunol 2010, 125:1413-1414.
12. Brighton Collaboration 2010. AEFI Case Definition Document. [Accessed 21 March 2011]. https://brightoncollaboration.org/public/what-we-do/standards/case-definitions/available-definitions/extras/0/link/Case_Definition_Format_Template.pdf.
13. Vogel F.R., Caillet C., Kusters I.C., Haensler J. Emulsion-based adjuvants for influenza vaccines. Expert Rev Vaccines 2009, 8:483-492.
14. World Health Organization (WHO) 2009. Characteristics of emergent influenza A (H1N1) viruses and recommendations for vaccine development. [Accessed 21 March 2011]. http://www.who.int/csr/resources/publications/swineflu/H1N1Vaccinevirusrecommendation26May2009.pdf.
15. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589.
16. Leroux-Roels I., Bernhard R., Gérard P., Dramé M., Hanon E., Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 2008, 3:e1665.
17. Rümke H.C., Bayas J.M., de Juanes J.R., Caso C., Richardus J.H., Campins M., et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008, 26:2378-2388.
18. Schwarz T.F., Horacek T., Knuf M., Damman H.G., Roman F., Dramé M., et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009, 27:6284-6290.
19. European Medicines Agency (EMA) 2010. Sixteenth pandemic pharmacovigilance update. [Accessed 21 March 2011]. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/04/WC500089611.pdf.
20. European Medicines Agency (EMA) 2010. Twenty-second pandemic pharmacovigilance update. [Accessed 21 March 2011]. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/08/WC500095870.pdf.
21. Mozzicato P. Standardised MedDRA queries: their role in signal detection. Drug Saf 2007, 30:617-619.
22. Kohl K.S., Magnus M., Ball R., Halsey N., Shadomy S., Farley T.A. Applicability, reliability, sensitivity, and specificity of six Brighton Collaboration standardized case definitions for adverse events following immunization. Vaccine 2008, 26:6349-6360.
23. Bonhoeffer J., Kohl K., Chen R., Duclos P., Heijbel H., Heininger U., et al. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 2002, 21:298-302.
24. Bonhoeffer J., Kohl K., Chen R., Duclos P., Heijbel H., Heininger U., et al. The Brighton Collaboration-enhancing vaccine safety. Vaccine 2004, 22:2046.
25. Bonhoeffer J., Heininger U., Kohl K., Chen R.T., Duclos P., Heijbel H., et al. Standardized case definitions of adverse events following immunization (AEFI). Vaccine 2004, 22:547-550.
26. Kohl K.S., Bonhoeffer J., Chen R., Duclos P., Heijbel H., Heininger U., et al. The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiol Drug Saf 2003, 12:335-340.
27. Kohl K.S., Gidudu J., Bonhoeffer J., Braun M.M., Buettcher M., Chen R.T., et al. The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine 2007, 25:5671-5674.
28. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) 1994. ICH Topic E2A: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. [Accessed 21 March 2011]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf.
29. Wharton M. Vaccine safety: current systems and recent findings. Curr Opin Pediatr 2010, 22:88-93.
30. Public Health Agency of Canada 2010. Vaccine Surveillance Report - Adverse Events following Immunization. Update: April 27, 2010. [Accessed 21 March 2011]. http://www.phac-aspc.gc.ca/alert-alerte/h1n1/vacc/addeve-eng.php.
31. Gibbons R.D., Amatya A.K., Brown C.H., Hur K., Marcus S.M., Bhaumik D.K., et al. Post-approval drug safety surveillance. Annu Rev Public Health 2010, 31:419-437.
32. Gold M.S., Gidudu J., Erlewyn-Lajeunesse M., Law B. Brighton collaboration Working Group on Anaphylaxis, Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study. Vaccine 2010, 28:4487-4498.
33. Seitz C.S., Bröcker E.B., Trautmann A. Vaccination-associated anaphylaxis in adults: diagnostic testing ruling out IgE-mediated vaccine allergy. Vaccine 2009, 27:3885-3889.
34. Chen W., Mempel M., Schober W., Behrendt H., Ring J. Gender difference, sex hormones, and immediate type hypersensitivity reactions. Allergy 2008, 63:1418-1427.
35. Soost S., Leynaert B., Almqvist C., Edenharter G., Zuberbier T., Worm M. Risk factors of adverse reactions to food in German adults. Clin Exp Allergy 2009, 39:1036-1044.